メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
Keio University ホーム
ヘルプ＆FAQ
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
舩越 建
皮膚科学
ウェブサイト
https://k-ris.keio.ac.jp/html/100005696_ja.html
h-index
1938
被引用数
23
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2009
2025
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(116)
類似のプロファイル
(6)
フィンガープリント
Takeru Funakoshiが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Nodular Melanoma
100%
Extramammary Paget's Disease
69%
Neoplasm
27%
Nivolumab
27%
Immune Checkpoint Inhibitor
26%
Immunotherapy
22%
Overall Survival
20%
Clinical Trial
16%
Adverse Event
16%
Biological Marker
15%
Lymph Node Metastasis
15%
Malignant Neoplasm
15%
Solid Malignant Neoplasm
15%
Pemphigus
15%
Immunoglobulin A
15%
Treatment Response
15%
Paclitaxel
15%
Disease
15%
Hazard Ratio
11%
Pembrolizumab
10%
Tumor Progression
10%
Retrospective Study
10%
Programmed Cell Death
10%
Fluorescence in Situ Hybridization
10%
Progression Free Survival
10%
Docetaxel
9%
Lymphocyte
9%
Arm
9%
Blister
9%
Immunohistochemistry
9%
Epirubicin
9%
Carboplatin
9%
Base
9%
Mucosal Melanoma
8%
Prognostic Factor
8%
Monotherapy
8%
Cutaneous Melanoma
8%
Breast Cancer
8%
Systemic Therapy
8%
Receptor Expression
7%
Randomized Controlled Trial
7%
Imatinib
7%
Pemphigoid
7%
Linear IgA Bullous Dermatosis
7%
Human Milk
7%
Adenylate Cyclase
7%
Epidermal Growth Factor Receptor 2
7%
Autoreactivity
7%
Tumor Suppressor Gene
7%
Vancomycin
7%
Pharmacology, Toxicology and Pharmaceutical Science
Paget Skin Disease
64%
Melanoma
38%
Neoplasm
25%
Malignant Neoplasm
19%
Adverse Event
18%
Epidermal Growth Factor Receptor 2
17%
Gamma Urogastrone
17%
Docetaxel
17%
Immunotherapy
16%
Nivolumab
16%
Epirubicin
15%
Remission
15%
Cisplatin
15%
Paclitaxel
15%
Pemphigus
15%
Trastuzumab
15%
Clinical Trial
14%
Infection
12%
Breast Cancer
12%
Overall Survival
11%
Immune Checkpoint Inhibitor
10%
Retrospective Study
9%
Pembrolizumab
8%
Solid Malignant Neoplasm
8%
Monotherapy
8%
Programmed Death 1 Ligand 1
7%
Cytotoxic T Lymphocyte Antigen 4
7%
T Lymphocyte Receptor
7%
Cytokeratin 19 Fragment
7%
Hydronephrosis
7%
Mitogen Activated Protein Kinase Kinase Inhibitor
7%
Autoantibodies
7%
Cohort Study
7%
Observational Study
7%
Imatinib
7%
Non Melanoma Skin Cancer
7%
Base
7%
Disease Model
7%
Desmoglein
7%
Bullous Skin Disease
7%
Randomized Controlled Trial
7%
Skin Abscess
7%
Corynebacterium amycolatum
7%
Cytokine Release Syndrome
7%
Pathogenicity
7%
Taste Disorder
7%
Wound
7%
Bexarotene
7%
Cutaneous T Cell Lymphoma
7%
Lamictal
7%
Keyphrases
Extramammary Paget's Disease
56%
Japanese Patients
24%
Melanoma Patients
15%
Drug Hypersensitivity
15%
KW-0761
15%
Gastroenteritis
13%
Ipilimumab
12%
Docetaxel
12%
Immune Checkpoint Inhibitors
11%
Japan
11%
Immune-related Adverse Events
10%
Cutaneous Angiosarcoma
10%
Drug Adverse Reaction
8%
Monotherapy
8%
Pembrolizumab
8%
Cisplatin
8%
Erythema multiforme
8%
Paclitaxel
8%
Oncologists
7%
Randomized Controlled Trial
7%
Stage III Melanoma
7%
Targeted Cancer Immunotherapy
7%
Metastatic Cutaneous Squamous Cell Carcinoma
7%
SARS-CoV-2 Infection
7%
Antitumor Therapeutics
7%
Viral Burden
7%
Absent in Melanoma 2 (AIM2)
7%
Androgen Receptor Expression
7%
Sugammadex
7%
Rocuronium
7%
Drug Reaction
7%
Advanced Solid Tumors
7%
Advanced Melanoma
7%
Eosinophilia
7%
Completion Lymph Node Dissection
7%
HER2-positive
7%
Graft-versus-host Disease (GvHD)
7%
Lamotrigine
7%
Acral
7%
Cutaneous Manifestations
7%
Clinicopathological Significance
7%
Apologizing
7%
Complete Remission
7%
Adjuvant Therapy
7%
Phase 1/2 Study
7%
Phase II Trial
7%
Skin Malignancy
7%
Weekly Docetaxel
7%
Epigenetic Mosaicism
7%
Capsule Endoscopy
7%
